MX2023006083A - Npp1 para usarse en el tratamiento de calcificacion de tejidos. - Google Patents

Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Info

Publication number
MX2023006083A
MX2023006083A MX2023006083A MX2023006083A MX2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A
Authority
MX
Mexico
Prior art keywords
calcification
npp1
treating tissue
provides
methods
Prior art date
Application number
MX2023006083A
Other languages
English (en)
Inventor
Anthony Quinn
Nelson Hsia
Tayeba Khan
Gregory Grabowsky
Zhiliang Cheng
W Charles O'neill
Kym Lynette ASKEW
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2023006083A publication Critical patent/MX2023006083A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona composiciones para usarse en el tratamiento de la deficiencia de NPP1 o una enfermedad asociada con NPP1 tal como la calcificación arterial idiopática infantil (IIAC), pseudoxantoma elástico, calcificación vascular en enfermedad renal crónica (VCCKD), resistencia a la insulina, raquitismo hipofosfatémico, isquemia del miocardio, calcificación de articulaciones, estrías angioides, y osificación del ligamento longitudinal posterior de la espina.
MX2023006083A 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos. MX2023006083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094943P 2014-12-19 2014-12-19
US201562249781P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
MX2023006083A true MX2023006083A (es) 2023-06-19

Family

ID=56127864

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017007946A MX2017007946A (es) 2014-12-19 2015-12-18 Metodos para tratar la calcificacion de tejidos.
MX2023006083A MX2023006083A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.
MX2022011281A MX2022011281A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017007946A MX2017007946A (es) 2014-12-19 2015-12-18 Metodos para tratar la calcificacion de tejidos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011281A MX2022011281A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Country Status (14)

Country Link
US (2) USRE49529E1 (es)
EP (2) EP3234116B1 (es)
JP (3) JP2018500315A (es)
KR (1) KR20170095367A (es)
CN (1) CN107109381A (es)
AU (1) AU2015364411A1 (es)
BR (1) BR112017012928A2 (es)
CA (1) CA2971414A1 (es)
CO (1) CO2017006032A2 (es)
ES (1) ES2899895T3 (es)
HK (1) HK1245662A1 (es)
MX (3) MX2017007946A (es)
RU (1) RU2770698C2 (es)
WO (1) WO2016100803A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
ES2899895T3 (es) 2014-12-19 2022-03-15 Inozyme Pharma Inc Procedimientos de tratamiento de calcificación tisular
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
CA3032467A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
WO2019067502A1 (en) * 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
EP3790628A4 (en) * 2018-05-08 2022-03-09 Yale University COMPOSITIONS AND METHODS TO REDUCE PROGRESSION OF NEPHROLITHIASIS
EP3844280A4 (en) * 2018-08-31 2022-09-14 Yale University ENPP1 POLYPEPTIDES AND METHODS OF USE THEREOF
KR20210142599A (ko) * 2019-01-18 2021-11-25 이노자임 파마, 인코포레이티드 Enpp1 또는 enpp3 결핍을 수반하는 질환의 치료
MX2022015772A (es) * 2020-06-09 2023-05-19 Inozyme Pharma Inc Proteínas enpp1 o enpp3 solubles y sus usos.
EP4247406A1 (en) * 2020-11-19 2023-09-27 Inozyme Pharma, Inc. Treatment of enpp1 deficiency and abcc6 deficiency

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
DK1032662T3 (da) 1997-11-07 2006-07-03 Trillium Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulation
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU3983701A (en) 2000-02-23 2001-09-03 Pxe International Inc Methods and composition for diagnosing and treating pseudoxanthoma elasticum andrelated conditions
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
NZ548612A (en) 2004-02-09 2009-11-27 Human Genome Sciences Inc Albumin fusion proteins comprising tandem GLP-1
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2012125182A1 (en) * 2011-03-11 2012-09-20 Synageva Biopharma Corp Npp1 fusion proteins
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
ES2899895T3 (es) * 2014-12-19 2022-03-15 Inozyme Pharma Inc Procedimientos de tratamiento de calcificación tisular
EP3298140B1 (en) * 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
US20180371434A1 (en) 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same

Also Published As

Publication number Publication date
JP2022003048A (ja) 2022-01-11
ES2899895T3 (es) 2022-03-15
USRE49529E1 (en) 2023-05-16
US20180318400A1 (en) 2018-11-08
EP3234116B1 (en) 2021-09-08
KR20170095367A (ko) 2017-08-22
US10493135B2 (en) 2019-12-03
CA2971414A1 (en) 2016-06-23
AU2015364411A1 (en) 2017-06-08
RU2017119466A (ru) 2019-01-21
JP2024010052A (ja) 2024-01-23
JP2018500315A (ja) 2018-01-11
MX2022011281A (es) 2022-10-18
RU2017119466A3 (es) 2019-12-20
HK1245662A1 (zh) 2018-08-31
EP3967755A1 (en) 2022-03-16
CN107109381A (zh) 2017-08-29
EP3967755B1 (en) 2024-03-27
BR112017012928A2 (pt) 2018-05-15
EP3234116A2 (en) 2017-10-25
RU2770698C2 (ru) 2022-04-21
EP3234116A4 (en) 2018-08-01
MX2017007946A (es) 2017-09-15
WO2016100803A3 (en) 2016-08-04
WO2016100803A2 (en) 2016-06-23
CO2017006032A2 (es) 2017-10-20

Similar Documents

Publication Publication Date Title
MX2022011281A (es) Npp1 para usarse en el tratamiento de calcificacion de tejidos.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2021000848A (es) Compuestos y sus usos para modular la hemoglobina.
EA201791093A1 (ru) Антитела к cd47, способы и применение
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
MY175708A (en) Dna antibody constructs and method of using same
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
MX2021003740A (es) El control efectivo y eficaz del fosfato serico para una osificacion optima.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
SG10201804034QA (en) Methods for treating hypotension
EA201500670A1 (ru) Egfr-направленная терапия неврологических нарушений и боли
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018002304A (es) Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2018011512A (es) Uso de insulina para promover el vaciamiento gástrico.
EP4328245A3 (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations